Resolution Therapeutics Announces the Appointment of Lisa Bright as Chair of its Board of Directors
London, 9 November 2022 - Resolution announced today the appointment of Lisa Bright as Chairman of its Board of Directors
READ MORE +
Harnessing the healing power of the macrophage
Resolution Therapeutics is developing macrophage cell therapies to treat diseases characterised by life-threatening inflammatory organ damage. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, manufacture and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes.
About Us
Resolution TX is a biotechnology company developing macrophage cell therapy to treat inflammatory organ disease.
MORE INFO +The Science
Our work builds on more than a decade of cutting-edge research demonstrating the therapeutic potential of macrophages.
MORE INFO +Careers
Interested in working on cutting-edge science in a fast-paced environment? We’d love to hear from you
MORE INFO +Publications
All the latest scientific publications underpinning our work by our scientific founders & groups.
MORE INFO +Latest News
Chairman's Statement
Resolution is at the forefront of a new kind of cell therapy. We’re treating inflammatory organ disease with macrophages, the cells that the body uses to resolve injury and heal wounds. Our work builds on a huge body of science understanding the role of macrophages as orchestrators of the wound healing process; coupled with our world-leading founders, a top-quality scientific staff and proprietary insight into macrophage biology and manufacturing, we are poised to improve the lives of countless patients worldwide.